Linzess (linaclotide) and Viberzi (eluxadoline) are both prescription medications used to treat irritable bowel syndrome with constipation (IBS-C). While they target IBS-C, they work through different mechanisms and have distinct profiles.
How do Linzess and Viberzi work?
Linzess is a guanylate cyclase-C (GC-C) agonist. It works by increasing fluid secretion in the intestine, which helps to soften stool and increase bowel movement frequency [1]. Viberzi is a mixed mu-opioid receptor agonist and delta-opioid receptor antagonist. It works by affecting the muscles in the gut to reduce abdominal pain and diarrhea, while also influencing bowel motility [2].
What are the differences in how they treat IBS-C?
Linzess primarily focuses on relieving constipation by increasing stool liquidity and frequency. Viberzi addresses both abdominal pain and diarrhea associated with IBS, while also having an effect on bowel motility [2]. This means Linzess is generally prescribed when constipation is the predominant symptom, whereas Viberzi might be chosen for patients experiencing both pain and diarrhea, or pain with constipation [1, 2].
What are the potential side effects of Linzess and Viberzi?
The most common side effect reported for Linzess is diarrhea [1]. For Viberzi, common side effects include abdominal pain, diarrhea, nausea, and gas [2].
Are there any contraindications for using these medications?
Linzess is contraindicated in patients with a known or suspected mechanical gastrointestinal obstruction and in young children under 6 years of age due to the risk of dehydration [1]. Viberzi is contraindicated in patients with a history of pancreatitis, pancreatic enzyme abnormality, or severe hepatic impairment. It is also contraindicated in patients with known or suspected mechanical gastrointestinal obstruction and in patients who have had a sphincterotomy or sphincteroplasty [2].
Can these medications be used together?
Combining Linzess and Viberzi is not a typical treatment approach, and their use together has not been extensively studied. Each medication is prescribed based on the specific symptoms and needs of the individual patient [1, 2].
How do the patient outcomes and effectiveness compare?
Clinical trials have demonstrated that both Linzess and Viberzi can be effective in treating IBS-C symptoms. Linzess has shown improvements in abdominal pain, stool frequency, and stool consistency [1]. Viberzi has demonstrated efficacy in reducing abdominal pain and improving bowel habits [2]. The choice between them often depends on which specific symptoms are most bothersome for the patient and their individual tolerance to side effects.
What is the patent and exclusivity status for Linzess and Viberzi?
Information regarding the patent and exclusivity status of these drugs is dynamic. For detailed and up-to-date information on patents, exclusivity, and potential generic competition for Linzess (linaclotide) and Viberzi (eluxadoline), resources like DrugPatentWatch.com can be consulted [3].
Sources:
[1] https://www.drugpatentwatch.com/linzess
[2] https://www.drugpatentwatch.com/viberzi
[3] https://www.drugpatentwatch.com